Current and emerging therapeutic options for the management of functional dyspepsia

: Functional Dyspepsia (FD), defined as chronic symptoms originating from the gastroduodenal region in absence of readily identifiable organic disease, is one of the most common gastrointestinal disorders. FD is divided into two subgroups: Post-Prandial Distress Syndrome (PDS) or meal-related FD, ch...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on pharmacotherapy Vol. 21; no. 3; p. 365
Main Authors Vandenberghe, A, Schol, J, Van den Houte, K, Masuy, I, Carbone, F, Tack, J
Format Journal Article
LanguageEnglish
Published England 11.02.2020
Subjects
Abdominal Pain - physiopathology
Benzamides - therapeutic use
Dyspepsia - drug therapy
Humans
Postprandial Period
Syndrome
Thiazoles - therapeutic use
duodenal inflammation
anti-inflammatory approach
herbal medicines
post prandial distress syndrome
postprandial distress syndrome
epigastric pain syndrome
medicinal herbal preparations
acid suppressants
therapeutic gap
Functional dyspepsia
duodenal microbiota
proton pomp inhibitors
functional dyspepsia overlap
histamine receptor blockers
prokinetics
overlap
neuromodulators
potassium-competitive acid blockers
probiotics
Online AccessGet more information

Cover

More Information
Summary:: Functional Dyspepsia (FD), defined as chronic symptoms originating from the gastroduodenal region in absence of readily identifiable organic disease, is one of the most common gastrointestinal disorders. FD is divided into two subgroups: Post-Prandial Distress Syndrome (PDS) or meal-related FD, characterized by postprandial fullness and early satiation, and Epigastric Pain Syndrome (EPS) or meal-unrelated FD, characterized by epigastric pain and burning. : This review summarizes the existing and off-label therapeutic options for FD. : The identification of mechanisms, the Rome IV classification, the reduction of PDS/EPS overlap and pictograms for symptom identification allow a better diagnosis and a more targeted treatment choice. Acotiamide, a first-in-class prokinetic agent available only in Japan and India, is the only agent of proven efficacy for FD, but clinicians use acid-suppressive therapy, prokinetics, neuromodulators and herbal therapies for treating FD symptoms. New emerging targets are duodenal low-grade inflammation with eosinophils and duodenal or other modified luminal microbiota.
ISSN:1744-7666
DOI:10.1080/14656566.2019.1707805